Anti-proliferative activity of RIHMS-Qi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases.
BMC Cancer
; 23(1): 1053, 2023 Nov 02.
Article
in En
| MEDLINE
| ID: mdl-37919708
ABSTRACT
BACKGROUND:
Breast cancer is the most common malignancy globally, and is considered a major cause of cancer-related death. Tremendous effort is exerted to identify an optimal anticancer drug with limited side effects. The quinoline derivative RIMHS-Qi-23 had a wide-spectrum antiproliferative activity against various types of cancer cells.METHODS:
In the current study, the effect of RIMHS-Qi-23 was tested on MCF-7 breast cancer cell line to evaluate its anticancer efficacy in comparison to the reference compound doxorubicin.RESULTS:
Our data suggest an anti-proliferative effect of RIMHS-Qi-23 on the MCF-7 cell line with superior potency and selectivity compared to doxorubicin. Our mechanistic study suggested that the anti-proliferative effect of RIMHS-Qi-23 against MCF-7 cell line is not through targeted kinase inhibition but through other molecular machinery targeting cell proliferation and senescence such as cyclophlin A, p62, and LC3.CONCLUSION:
RIMHS-Qi-23 is exerting an anti-proliferative effect that is more potent and selective than doxorubicin.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Agents
Limits:
Female
/
Humans
Language:
En
Journal:
BMC Cancer
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article
Affiliation country:
Egypt